About one in five men with prostate cancer had osteoporosis in pooled studies

Design

Systematic review and meta-analysis of 52 prevalence studies

Population

91,913 men with prostate cancer at all disease stages

Primary outcome

Prevalence of osteoporosis and low bone mass

Effect

Osteoporosis 22.0% (95% CI 19.9 to 24.1); low bone mass 41.7% (36.6 to 46.9); I² above 95%

This systematic review and meta-analysis included 52 studies with 91,913 men with prostate cancer. Osteoporosis was defined mainly by a bone mineral density T-score of -2.5 or lower, and low bone mass by a T-score from above -2.5 to below -1.0.

Pooled prevalence of osteoporosis was 22.0% (95% CI 19.9 to 24.1), and of low bone mass 41.7% (36.6 to 46.9). Heterogeneity was extreme (I² 99.5% and 95.9%), and differences between subgroups were mostly due to methods, so subgroup comparisons are exploratory. A link with androgen deprivation duration was not found, but data were available for only about 20 to 24 studies.

The review measured prevalence only. It did not assess fractures, screening effectiveness or treatments, and it cannot show that any intervention lowers fracture risk. Even so, the frequency of low bone density argues for bone health being part of routine prostate cancer care, especially in men on androgen deprivation.

• Consider bone density testing in men with prostate cancer, particularly those starting or on androgen deprivation therapy.
• Check vitamin D, calcium intake and falls risk as part of the same review.
• Follow your local guideline for treatment thresholds; this review did not test treatments.
• Repeat bone assessment at intervals set by risk, not only after a fracture.
• Record the method used so results are comparable over time.

Why it matters

Bone health is often an afterthought in prostate cancer care, though the pooled prevalence suggests it affects many patients.

Don't overread it

A prevalence review with extreme heterogeneity does not show that screening or treatment prevents fractures.

The statistics, in plain English

An I² of 99% means the studies disagreed far more than chance would explain, so 22% is an average of very different populations and methods rather than a figure to expect in your clinic. A prevalence cannot say how many fractures could be prevented.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.